Endothelin receptors in light-induced retinal degeneration.
Excessive light exposure leads to retinal degeneration in albino animals and exacerbates the rate of photoreceptor apoptosis in several retinal diseases. In previous studies we have described the presence of endothelin-1 (ET-1) and its receptors (ET-A and ET-B) in different sites of the mouse retina, including the retinal pigment epithelium, the outer plexiform layer (OPL), astrocytes, the ganglion cell layer (GCL), and vascular endothelia. After light-induced degeneration of photoreceptors, endothelinergic structures disappear from the OPL, but ET-1 and ET-B immunoreactivities increase in astrocytes. Here, we present novel observations about the course of light-induced retinal degeneration in BALB-c mice exposed to 1500 lux during 4 days with or without treatment with tezosentan, a mixed endothelinergic antagonist. Retinal whole mounts were immunostained with anticleaved caspase-3 (CC-3) serum to identify apoptotic photoreceptor cells within the outer nuclear layer (ONL). Glial activation was measured as glial fibrillary acidic protein (GFAP) immunoreactivity in retinal whole mounts and in Western blots from retinal extracts. Tezosentan treatment significantly reduced both the number of CC3-immunoreactive cells and GFAP levels, suggesting that inhibition of endothelinergic receptors could play a role in photoreceptor survival. Using confocal double immunofluorescence, we have observed that ET-A seems to be localized in bipolar cell dendrites, whereas ET-B is localized in horizontal cells. Our observations suggest the existence of an endothelinergic mechanism modulating synaptic transmission in the OPL. This mechanism could perhaps explain the effects of tezosentan treatment on photoreceptor survival.
Torbidoni
Vanesa
V
Facultad de Ciencias Biomédicas, Universidad Austral, Pilar, Buenos Aires B1629AHJ, Argentina.
Iribarne
María
M
Suburo
Angela M
AM
D000818:Animals; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D007150:Immunohistochemistry; D008027:Light / Q000009:adverse effects*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010857:Pigment Epithelium of Eye / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D011832:Radiation Injuries / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D044022:Receptor, Endothelin A / Q000378:metabolism* / Q000528:radiation effects; D044023:Receptor, Endothelin B / Q000378:metabolism* / Q000528:radiation effects; D012162:Retinal Degeneration / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D013777:Tetrazoles / Q000494:pharmacology; D013997:Time Factors; D014665:Vasodilator Agents / Q000494:pharmacology
D005904:Glial Fibrillary Acidic Protein; D011725:Pyridines; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D013777:Tetrazoles; D014665:Vasodilator Agents; C120582:tezosentan; C505409:Casp3 protein, mouse; D053148:Caspase 3; D020169:Caspases